Cormorant Pharmaceuticals Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$520M
Cormorant Pharmaceuticals General Information
Description
Provider of pharmaceutical services. The company primarily focuses on developing therapeutics and related services for cancer and other rare diseases.
Contact Information
Website
www.cormorantpharma.comCorporate Office
- Karolinska Institute Science Park
- Fogdevreten 2A, Stockholm
- 171 65 Solna
- Sweden
Corporate Office
- Karolinska Institute Science Park
- Fogdevreten 2A, Stockholm
- 171 65 Solna
- Sweden
Cormorant Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 05-Jul-2016 | $520M | Completed | Generating Revenue | ||
| 1. Buyout/LBO | Completed | Generating Revenue |
Cormorant Pharmaceuticals Patents
Cormorant Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201509812-D0 | Cancer companion diagnostics | Inactive | 05-Jun-2015 | ||
| US-20080118517-A1 | Chemokine specific immunoglobulin for prevention and treatment of cell proliferative, skin, inflammatory and autoimmune disorders | Active | 16-Dec-2002 | ||
| US-7622559-B2 | Chemokine specific immunoglobulin for prevention and treatment of cell proliferative, skin, inflammatory and autoimmune disorders | Inactive | 16-Dec-2002 | ||
| AU-2003299641-A1 | Human monoclonal antibodies against interleukin 8 (il-8) | Active | 16-Dec-2002 | ||
| AU-2003299641-B2 | Human monoclonal antibodies against interleukin 8 (il-8) | Inactive | 16-Dec-2002 | C07K16/244 |
Cormorant Pharmaceuticals Signals
Cormorant Pharmaceuticals Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Flerie | Venture Capital | Majority |
Cormorant Pharmaceuticals Investments (2)
Cormorant Pharmaceuticals’s most recent deal was a Later Stage VC with Zai Lab for . The deal was made on 28-Jun-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zai Lab | 28-Jun-2017 | Later Stage VC | Pharmaceuticals | ||
| Genmab (HuMax-IL8) | 30-May-2012 | Corporate Asset Purchase | Buildings and Property |
Cormorant Pharmaceuticals FAQs
-
When was Cormorant Pharmaceuticals founded?
Cormorant Pharmaceuticals was founded in 2010.
-
Where is Cormorant Pharmaceuticals headquartered?
Cormorant Pharmaceuticals is headquartered in Solna, Sweden.
-
What is the size of Cormorant Pharmaceuticals?
Cormorant Pharmaceuticals has 2 total employees.
-
What industry is Cormorant Pharmaceuticals in?
Cormorant Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Cormorant Pharmaceuticals a private or public company?
Cormorant Pharmaceuticals is a Private company.
-
What is the current valuation of Cormorant Pharmaceuticals?
The current valuation of Cormorant Pharmaceuticals is .
-
What is Cormorant Pharmaceuticals’s current revenue?
The current revenue for Cormorant Pharmaceuticals is .
-
Who are Cormorant Pharmaceuticals’s investors?
Flerie has invested in Cormorant Pharmaceuticals.
-
When was Cormorant Pharmaceuticals acquired?
Cormorant Pharmaceuticals was acquired on 05-Jul-2016.
-
Who acquired Cormorant Pharmaceuticals?
Cormorant Pharmaceuticals was acquired by Bristol-Myers Squibb.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process